Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088

被引：2
|
作者：
Loong, H. H. F. [1 ]
Daniele, G. [2 ]
Yang, T-Y. [3 ]
Leal, T. A. [4 ]
Goto, K. [5 ]
Shinno, Y. [6 ]
Nishino, K. [7 ]
Sakamoto, T. [8 ]
Felip, E. [9 ]
Ruffinelli, J. C. [10 ]
Gallot, N. [11 ]
Wang, Z. [12 ]
Chen, C. [13 ]
Brennan, B. [13 ]
Pu, S-F. [14 ]
Kornacker, M. [15 ]
Grassi, P. [16 ]
Le, X. [17 ]
Tan, D. S. W. [18 ]
Goh, B-C. [19 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Fdn Policlin Univ Agostino Gemelli IRCC, Phase 1 Unit, Rome, Italy
[3] Taichung Vet Gen Hosp, Chest Med, Taichung, Taiwan
[4] Emory Univ, Hematol & Oncol, Atlanta, GA USA
[5] Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan
[6] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
[7] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan
[8] Tottori Univ, Dept Multidisciplinary Internal Med, Div Resp Med & Rheumatol, Tottori, Japan
[9] Vall dHebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain
[10] Hosp Duran & Reynals, Dept Med Oncol, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Spain
[11] ClinBAY Ltd, Stat, Limassol, Cyprus
[12] Bayer HealthCare Pharmaceut Inc, Oncol, Cambridge, MA USA
[13] Bayer Healthcare Pharmaceut Inc, Clin Pharmacol, Whippany, NJ USA
[14] Bayer HealthCare Pharmaceut Inc, Benefit Risk Management, Pharmacovigilance, Whippany, NJ USA
[15] Bayer Consumer Care, Early Clin Dev Oncol, Basel, Switzerland
[16] Bayer SpA, RED Oncol, Milan, Italy
[17] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[18] Natl Canc Ctr Singapore, Dept Med Oncol, Singapore, Singapore
[19] Natl Univ Canc Inst, Dept Hematol Oncol, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2409
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1320MO
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of poziotinib in treatment-naive HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
    Sun, S.
    Prelaj, A.
    Baik, C.
    Le, X.
    Garassino, M.
    Wollner, M.
    Haura, E.
    Piotrowska, Z.
    Socinski, M.
    Dreiling, L.
    Bhat, G.
    Lebel, F.
    Cornelissen, R.
    ANNALS OF ONCOLOGY, 2022, 33 : S13 - S13
  • [2] Understanding the diagnostic and treatment landscape in EGFRm advanced non-small cell lung cancer (aNSCLC) patients with exon 20 insertion mutations (Ex20ins)
    Bailey, H.
    Nasirova, F.
    Sermon, J.
    Rodrigues, B.
    Khela, K.
    Hall, J.
    Last, M. J.
    Penton, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S975 - S976
  • [3] CUTANEOUS TOXICITIES WITH AMIVANTAMAB FOR NON-SMALL CELL LUNG CANCER ( NSCLC) WITH EXON 20 INSERTION MUTATION (EX20INS): A PRACTICAL GUIDE AND BEST PRACTICES FOR MANAGEMENT
    Singh-Kandah, Shahnaz
    Wang, Kaiwen
    Xia, Karen
    Johnson, Andy
    D'Andrea, Denise
    Dougherty, Lindsay
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [4] REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations
    Yu, Helena Alexandra
    Besse, Benjamin
    Nishio, Makoto
    Wei, Ying Cheng Li
    Wacheck, Volker
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
    Brazel, Danielle
    Kroening, Gianna
    Nagasaka, Misako
    BIODRUGS, 2022, 36 (06) : 717 - 729
  • [6] Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
    Danielle Brazel
    Gianna Kroening
    Misako Nagasaka
    BioDrugs, 2022, 36 : 717 - 729
  • [7] Indirect comparison of mobocertinib trial data vs real-world data in patients with EGFR exon 20 insertion (ex20ins)+ non-small cell lung cancer (NSCLC)
    Christopoulos, P.
    Prawitz, T.
    Hong, J-L.
    Lin, H. M.
    Hernandez, L.
    Jin, S.
    Tan, M.
    Proskorovsky, I.
    Lin, J.
    Zhang, P.
    Patel, J.
    Ou, S-H. I.
    Thomas, M.
    Stenzinger, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S49 - S49
  • [8] Comprehensive analysis of next generation sequencing and ARMS-PCR for detecting EGFR exon 20 insertion (ex20ins) mutations in Chinese non-small cell lung cancer patients
    Xu, Yuyin
    Jia, Liqing
    Jiang, Ling
    Wang, Haochen
    Jiang, Lin
    Feng, Xu
    Wei, Ran
    Yao, Qianlan
    Ren, Min
    Xue, Tian
    Li, Yuan
    Zhu, Xiaoli
    Zhou, Xiaoyan
    Bai, Qianming
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (05) : 986 - 997
  • [9] Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)
    Trigo, J.
    Cho, B. C.
    Park, K.
    Girard, N.
    Viteri, S.
    Garrido, P.
    Krebs, M. G.
    Thayu, M.
    Knoblauch, R. E.
    Xie, J.
    Bauml, J. M.
    Schnepp, R. W.
    Londhe, A.
    Mahadevia, P.
    Leighl, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S38 - S39
  • [10] Mechanisms of resistance to BAY 2927088, the first reversible inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Uzunbas, Gizem Karsli
    McVeigh, Quinn
    Gupta, Akansha
    Hoyt, Stephanie
    Doucette, Kristen
    Keshishian, Hasmik
    Carr, Steven
    Yang, Xiaoping
    Root, David
    Cherniack, Andrew D.
    Siegel, Franziska
    Siegel, Stephan
    Meyerson, Matthew
    Greulich, Heidi
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
12345